|
Vaccine Therapy in Treating Women With Metastatic Breast Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Vaccine Therapy in Treating Women With Metastatic Breast Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Vaccine Therapy in Treating Women With Metastatic Breast Cancer Clinical research trials and Vaccine Therapy in Treating Women With Metastatic Breast Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Vaccine Therapy in Treating Women With Metastatic Breast Cancer. Vaccine Therapy in Treating Women With Metastatic Breast Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Vaccine Therapy in Treating Women With Metastatic Breast Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Vaccine Therapy in Treating Women With Metastatic Breast Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vaccine Therapy in Treating Women With Metastatic Breast Cancer  Vaccine Therapy in Treating Women With Metastatic Breast Cancer
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
For Condition: recurrent breast cancer,stage 4 breast cancer
Status: Completed
Sponsor(s): Earle A. Chiles Research Institute ,
Synopsis: RATIONALE: Vaccines made from breast cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccines made from breast cancer cells in treating women with metastatic breast cancer.
Details: OBJECTIVES: I. Determine the safety and toxicity of vaccination strategies employing a CD80-transfected allogeneic breast cancer cell line (MDA-MB-231). II. Assess the immunologic response of lymphocytes isolated from lymph nodes draining the vaccination site following a single dose of CD80-transfected MDA-MB-231. III. Assess the development of systemic immunity following multiple injections of CD80-transfected MDA-MB-231. IV. Observe for tumor regression. PROTOCOL OUTLINE: This is a dose escalation study. Patients receive intradermal vaccinations containing CD80-transfected cells with or without sargramostim (GM-CSF) or with or without BCG. Vaccinations are administered every 2 weeks for 6 weeks and then monthly for 3 months. Patients may receive 1 of 2 different doses of GM-CSF. GM-CSF is administered with the vaccination, then every 12 hours for 7 days. Monthly vaccinations may continue as long as response is shown. Cohorts of 5 patients each are treated at each dose/combination. Each cohort completes treatment before the next cohort is accrued. Patients are followed at weeks 4 and 8, then every 2 months for 6 months, then every 3 months for 1 year, and then every 6 months until disease progression. PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study within 18 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically proven metastatic breast cancer - Stage IV disease patients who have either been treated to maximal response or who have had high dose chemotherapy or a marrow ablative regimen (if they meet immunologic criteria and have not received more than 2 chemotherapy regimens for treatment of metastatic disease) - Patients with advanced stage disease who: *Received at least 1 standard chemotherapy regimen, but no more than 2, for treatment of metastatic disease *Refused chemotherapy *Refused or progressed despite hormonal therapy Measurable or evaluable disease Positive or negative for HLA-A2 Must have superficial inguinal or axillary lymph nodes that are free of tumor involvement and are surgically accessible No symptomatic or acutely life threatening tumor that is judged likely to require intervention with alternative modalities within 3 months No brain metastases Hormone receptor status: Not specified --Prior/Concurrent Therapy-- Biologic therapy: At least 4 weeks since prior specific or nonspecific immunotherapy, unless there is obvious progression of metastatic disease, and recovered Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy, unless there is obvious progression of metastatic disease, and recovered Endocrine therapy: At least 4 weeks since prior steroids, unless there is obvious progression of metastatic disease, and recovered Radiotherapy: Concurrent radiotherapy allowed for local control of disease Surgery: Not specified --Patient Characteristics-- Age: 18 and over Sex: Female Menopausal status: Not specified Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: WBC greater than 3,000/mm3 Hepatic: Not specified Renal: - BUN less than 25 mg/dL - Creatinine less than 1.8 mg/dL Cardiovascular: - No ischemic or congestive cardiac disease requiring chronic medication - No New York Heart Association class III or IV heart disease - No evidence of ischemic change or ventricular ectopy (greater than 4/min) on electrocardiogram (EKG) - No evidence of type II arterial-ventricular block - No evidence of current cardiac disease by stress test and EKG Other: - HIV negative - No active infection requiring treatment - No psychiatric illness - No history of seizure disorder - No other prior malignancy within the past 10 years except squamous or basal cell skin cancer or carcinoma in situ of the cervix
Total Enrollment:
Location and Contact Information:
Overall Study Official:
WalterUrba, Study Chair, Earle A. Chiles Research Institute
Earle A. Chiles Research Institute at Providence Portland Medical Center
Portland, Oregon, 97213-2967
United States
Additional Information:
Study ID Numbers: CDR0000066010; PPMC-IRB-94-78,NCI-V98-1379,OCC-ONC-9408-L
Study Start Date: August 1996
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003184
Other Stage 4 Breast Cancer Studies:
1. Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
2. Bexarotene in Treating Patients With Metastatic Breast Cancer
3. Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer
4. Paclitaxel With or Without Trastuzumab in Treating Patients With Inoperable, Recurrent, or Metastatic Breast Cancer
5. SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer
Related Studies:
Other stage 4 breast cancer Clinical Trials
Other Oregon Clinical Trials
Other Portland Clinical Trials
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
|
|
|
|
|
|
|
|
